Back to search

Article

Opportunities and Resistance to Signal-Targeted Therapies in Pancreatic Cancer: What Can we Learn from Proteomic Studies?

2018-02-02

Abstract excerpt

In metastatic pancreatic cancer patients non eligible to surgery, signal-targeted therapies so far failed to show a significant amelioration of survival. These therapeutic options were tested in Phase II/III clinical trials mostly in combination with the reference treatment Gemcitabine. These innovative therapies aim at annihilating the oncogene dependency; they also aim at renormalizing the tumoral stroma to allo...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
f3373feb-c0e3-5560-b5fe-bfaefc6a6d68
DOI
10.20944/preprints201802.0013.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Opportunities and Resistance to Signal-Targeted Therapies in Pancreatic Cancer: What Can we Learn from Proteomic Studies?DOI 10.20944/preprints201802.0013.v1
Opportunities and Resistance to Signal-targeted Therapies in Pancreatic Cancer: What Can We Learn from Proteomic Studies?Semantic proximity
Molecular Pathology of Pancreatic Cancer: From Bench-to-Bedside TranslationSemantic proximity
Molecular biology of pancreatic cancer.Semantic proximity
Key biological processes driving metastatic spread of pancreatic cancer as identified by multi-omics studies.Semantic proximity
Recent insights into the biology of pancreatic cancerSemantic proximity
Molecular biology of pancreatic cancer; oncogenes, tumour suppressor genes, growth factors, and their receptors from a clinical perspectiveSemantic proximity
p21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation.Semantic proximity
Molecular dissection of pancreatic cancer signaling: Toward targeted therapies for KRAS, MDM2-TP53, EGFR, and PI3K/AKT/mTOR.Semantic proximity
A proteomic signature and potential pharmacological opportunities in the adaptive resistance to MEK and PI3K kinase inhibition in pancreatic cancer cells.Semantic proximity
Pancreatic Cancer Intrinsic PI3Kα Activity accelerates Metastasis and rewires Macrophage ComponentSemantic proximity
Proteomics in pancreatic cancer researchSemantic proximity
Emerging role of the KRAS-PDK1 axis in pancreatic cancer.Semantic proximity
Select a neighboring publication to make it the new centre.